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The relationship between panic disorder and nonpsychiatric medical illness is complex, 
but some evidence suggests hat panic disorder increases risk for a variety of nonpsychi- 
atric medical conditions. Given the demonstrated fficacy of cognitive behavioral ther- 
apy (CBT) for panic disorder, we were interested in evaluating the effects of CBT for 
panic disorder on nonpsychiatric medical symptoms among these patients. Patients were 
randomized to a 12-week group-administered CBT protocol (n = 22) or a delayed- 
treatment conlrol (n = 24). Treated patients howed marked improvement i  both anxi- 
ety symptoms and physical health symptom ratings that were evident at midtreatment 
and were maintained through a 6-month follow-up period. Despite comparable rates 
of change, changes in anxiety symptoms did not appear to mediate the relationship be- 
tween treatment and improved physical health ratings. These findings indicate that 
CBT appears to have an immediate and long-term beneficial impact on physical 
health and that this effect is independent from its impact on anxiety symptoms. 
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Epidemiological reports indicate that a variety of medical conditions are 
more prevalent in those with a lifetime history of an anxiety disorder (Wells, 
Golding, & Burnam, 1989). Panic disorder in particular is frequently com- 
plicated by the presence of nonpsychiatric medical conditions. The associa- 
tion between panic disorder and cardiorespiratory disorders uch as asthma, 
chronic obstructive pulmonary disease, and mitral valve prolapse is well 
established (Gorman et al., 1988; Karajgi, Rifkin, Doddi, & Kolli, 1990; 
Weissman, Markowitz, Ouellette, Greenwald, & Kahn, 1990; Zandbergen et
al., 1991). 
The relationship between panic disorder and nonpsychiatric medical ill- 
ness is complex. It appears that nonpsychiatric medical conditions can con- 
tribute to the development of panic disorder (Kahn, Drusin, & Klein, 1987; 
Raj, Corvea, & Dagon, 1993) and/or exacerbate panic disorder symptoms 
(McCue & McCue, 1984). In addition, increasing evidence suggests hat panic 
disorder can contribute to the development of physical conditions and/or 
exacerbate existing physical conditions (Karajgi et al., 1990; Kawachi et al., 
1994). For example, longitudinal evaluation of panic disorder indicates an 
increased risk for a number of medical conditions (e.g., hypertension, migraine 
headaches, ulcer, thyroid disease) compared to patients with other anxiety 
conditions and the general population (Rogers et al., 1994). 
The effect of stress on the immune system is one possible pathway to 
explain the relationship between anxiety and physical health. Stress is fre- 
quently associated with changes in immune parameters (Cacioppo, 1993; 
Glaser et al., 1990). Moreover, stress has been linked to increases in infec- 
tious illness (Kiecolt-Glaser & Glaser, 1995). Thus, chronic and debilitating 
conditions such as panic disorder are likely to compromise immune functioning. 
Findings from immune studies of patients with panic disorder are somewhat 
mixed, though alterations in immune measures have been noted (Andreoli et al., 
1992; Coplan et al., 1999; Marazziti et al., 1992; Rapaport, 1998; Rapaport & 
Stein, 1994). However, we are not aware of studies that have evaluated 
whether panic disorder also increases risk for infectious illness. 
Fortunately, there are effective means of treating panic disorder. Pharmaco- 
logical and psychosocial treatments have been found to be efficacious (Wolfe 
& Maser, 1994). In particular, cognitive behavioral therapy (CBT) for panic 
disorder has been found to be extremely effective in ameliorating panic- 
related symptoms using both individual (Barlow, Craske, Cerney, & Klosko, 
1989) and group-administered (Telch et al., 1993) treatment. In addition, 
patients completing CBT show marked improvements in overall quality of 
life (Telch, Schmidt, Jaimez, Jacquin, & Harrington, 1995). For example, 
CBT for panic disorder produces marked improvements in familial, social, 
and vocational quality-of-life indices (Telch et al., 1995). 
Little is known, however, about he effects of treatment on physical health 
outcomes in patients with panic disorder. There is some suggestion that phar- 
macological treatment for panic disorder may positively affect certain cardiac 
factors, including heart rate variability (Klein et al., 1995; Tucker et al., 
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1997), as well as cardiac conditions uch as mitral valve prolapse (Coplan, 
Papp, King, & Gorman, 1992). On the other hand, some pharmacotherapy 
interventions appear to adversely affect cardiovascular functioning (Roth et 
al., 1992; Taylor & Hayward, 1990). For example, tricyclic antidepressants 
appear to increase risk for hypertension (Louie, Louie, & Lannon, 1992). We 
could not find studies evaluating the effects of CBT for panic disorder on 
nonpsychiatric medical outcomes. 
In the present study, we sought o extend previous work on the interplay 
between panic disorder and physical health by examining the effects of CBT 
for panic disorder on nonpsychiatric medical symptoms. Because CBT has 
been found to substantially decrease anxiety symptoms and to improve qual- 
ity of life, and because high levels of anxiety symptoms appear to be related 
to a variety of nonpsychiatric medical problems, it was hypothesized that 
treatment-related alleviation of distress would have a significant impact on 
physical health symptoms. Specifically, patients completing CBT for panic 
disorder were expected to show fewer nonpsychiatric physical symptoms rel- 
ative to a wait-list control condition. If CBT did produce positive physical health 
outcomes, we were also interested in evaluating the role of possible mediating 
(e.g., decreased anxiety symptoms) and moderating factors (e.g., presence of a 
chronic nonpsychiatric medical condition) affecting this relationship. 
Method 
Participants 
The clinical sample consisted of 46 patients 1 meeting the following crite- 
ria: (a) principal DSM-IV (American Psychiatric Association, 1994) Axis I 
diagnosis of panic disorder with or without agoraphobia, (b) no change in 
medication type or d se during the 8 weeks prior to treatment, (c) no evi- 
dence of serious uicide intent, (d) no evidence of current substance abuse, 
and (e) no evidence of current or past schizophrenia, bipolar disorder, or 
organic mental disorder. Sixty-three percent of the patients were female, with 
a mean age of 37.9 years (SD = 12.5). The majority of these patients were 
Caucasian (80.4%), married (56.5%), and employed (71.7%). The majority 
(71%) received adiagnosis of panic disorder with agoraphobia and 41% had 
at least one co-occurring Axis I diagnosis (e.g., 18% major depression, 13% 
social anxiety disorder). Approximately half of the sample participants were 
medicated during the study (antidepressants 13%, anxiolytics 28%, both anti- 
l Some of the patients in the present report took part in a study reported previously (Schmidt 
et al., 2000). Administration of the PHRF was initiated toward the end of recruitment for the 
Schmidt et al. study such that two groups of patients (n = i2) randomized to the CBT group 
and two groups of patients (n = 10) randomized to the delayed treatment group. The present 
study combines these patients with an additional four groups of patients who were also random- 
ized to CBT (two groups: n = 10) or delayed treatment ( wo groups: n = 14). PHRF data were 
not reported in the earlier study. 
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depressants and anxiolytics 17%). Physical health status and medical morbid- 
ity were not selection criteria. 
Procedure 
Patients were selected from applicants who presented for evaluation at an 
academic research center specializing inthe assessment and treatment ofanx- 
iety disorders. Diagnostic assessment was based on an initial phone screening 
interview followed by a face-to-face structured clinical interview using the 
SCID-NP (First, Spitzer, Gibbon, & Williams, 1994). Randomly selected video- 
taped interviews from this sample indicated perfect interrater agreement for a 
primary diagnosis of panic disorder (10/10). 
After 5 to 7 treatment-eligible patients had completed the baseline assess- 
ment, this "group" was assigned to one of two conditions: CBT or a delayed 
treatment control. Four groups (n = 22) were assigned to the CBT condition 
and received a group-administered cognitive behavioral treatment that con- 
sisted of 12 sessions over a 12-week period (cf. Schmidt et al., 2000). Each 
session lasted approximately 120 minutes. The treatment protocol included 
four major components: (a) education and corrective information regarding 
the etiology and maintenance of panic disorder, (b) cognitive therapy tech- 
niques aimed at helping the patient o identify and alter faulty appraisals of 
threat hat contribute to panic occurrence, (c) interoceptive exposure xer- 
cises designed to reduce patients' fears of somatic ues through the repeated 
exposure to feared bodily sensations, and (d) instruction for conducting in 
vivo exposure xercises designed to reduce patients' fears of external situa- 
tions through repeated exposure to a fear hierarchy. Patients assigned to the 
treatment conditions were reassessed immediately following treatment and 6 
months after treatment. 
Four groups (n = 24) were assigned to the delayed treatment control con- 
dition. Patients in this condition were reassessed after 12 weeks and then 
received treatment but were not assessed further. 
In the active treatment group, treatment integrity was maintained by utiliz- 
ing a structured and manualized treatment protocol (Safety Maneuver Eli- 
mination for Panic Disorder; Schmidt, 1994)that describes the specific 
goals and strategies for each session. An independent rater's assessment of
adherence (Young, Beck, & Budenz, 1983) to the treatment protocol has 
yielded 100% adherence in a randomly selected set of videotaped treatment 
sessions. The first author administered the treatment to all groups. He is a 
licensed clinical psychologist with approximately 10 years of experience 
with cognitive-behavioral treatment of anxiety disorders. In each group, a 
graduate f llow in clinical psychology, a psychiatry resident, or a psychiatrist 
acted as co-facilitator. 
All 46 subjects who completed the baseline were assessed at posttreat- 
merit. All of the patients in the active treatment group completed the treat- 
ment (completing at least 11 of 12 sessions). Patients were allowed to 
reschedule a maximum of 3 sessions with those sessions being rescheduled 
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within a few days of the scheduled session. Five of the treated subjects did 
not complete the 6-month follow-up (they could not be contacted because of 
address changes). Comparisons between those completing treatment and 
those lost to follow-up indicated no significant differences in demographics, 
physical health parameters, and symptom severity at pretreatment or post- 
treatment (ps > .05). 
Measbtres 
A multimodal assessment battery tapping the major clinical dimensions 
of panic disorder was administered to all participants at baseline and post- 
treatment. The same battery was administered tothose in the active treatment 
group at follow-up. Physical health assessments were made at all assess- 
ment periods as well as midway during the treatment or waiting period (Week 
6). One of the anxiety measures was also administered during the midtreat- 
merit assessment. Clinician ratings were made by raters masked to treatment 
condition. 
Panic Disorder Severity Scale (PDSS). The PDSS is a semistructured inter- 
view rating scale for panic disorder (Shear et al., 1997) that includes ratings 
of panic frequency and intensity, anticipatory anxiety, avoidance of sensa- 
tions and situations, and impairment in work and social functioning. Each of 
these symptoms is rated on a 0 (none) to 4 (extreme) scale. In the present 
report, a composite score was utilized (i.e., average score of all items). The 
PDSS has good psychometric properties (Shear et al.). In this sample, two 
clinicians making PDSS ratings in a dual interview were found to have high 
reliability (average r = .91). 
Sheehan Patient-Rated Anxiety Scale (SPRAS). The SPRAS (Sheehan, 1983) 
is a widely used self-report scale for assessing the intensity of anxiety symp- 
toms. The SPRAS has demonstrated a equate t st-retest reliability (r = .67) and 
is highly associated with other measures of anxiety and overall impairment in 
panic disorder samples (Schmidt, Staab, Trakowski, & Sammons, 1997). In 
the present sample the SPRAS shows high internal consistency (~ = .90). 
General Health Survey (GHS). The GHS measures perceptions about health 
and includes a checklist for assessing the presence of chronic physical ill- 
nesses (e.g., hypertension, asthma, arthritis) and a 6-month istory of visits to 
health professionals. The GHS has been validated with nonpsychiatric and 
psychiatric samples (McHorney, Ware, Lu, & Sherbourne, 1994; McHorney, 
Ware, & Raczek, 1993). In the present report, we focus only on reported 
physical illnesses. 
Physical Health Rating Form (PHRF). The PHRF is an 11-item, clinician- 
administered measure that focuses on the occurrence of physical illness dur- 
ing the past 30 days. Because self-report methods focusing on specific, well- 
operationalized symptoms how better agreement with physician diagnoses 
(Orts et al., 1995), patients are given explicit instructions to only endorse spe- 
cific physical health symptoms arising from medical conditions and to 
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exclude symptoms resulting from their anxiety condition. The PHRF covers a 
number of related domains, including: (a) disability related to physical ill- 
ness, (b) frequency of physical health symptoms, and (c) perceived physical 
health status. Questions pertaining to the physical health disability score 
include: (a) number of days physically ill, (b) number of days missed work or 
unable to complete normal daily activities as a result of physical illness, (c) 
number of doctor visits, and (d) number of hospitalizations. Items used to 
assess frequency of specific symptoms include the number of days experienc- 
ing: (a) infections (e.g., flu, common cold), (b) respiratory illness (e.g., 
asthma), (c) gastrointestinal illness (e.g., ulcer), (d) cardiovascular illness 
(e.g., MVP), (e) headaches (including migraines), and (f) other illness symp- 
toms. The items targeting specific symptoms were rated on a scale ranging 
from 0 days to 5 + days. Finally, the overall perceived physical health rating 
was made using the following range: excellent (0), very good (1), good (2), 
fair (3), and poor (4). To score the scale, responses to each item were trans- 
formed to range from 0 to 5 such that each item was weighted equally, then 
summed across the 11 items (¢x = .59). 
Results 
Description of Nonpsychiatric Medical Comorbidity 
and Physical Health Status 
Consistent with previous reports, patients with panic disorder eported a
substantial mount of medical comorbidity. Approximately half (56%) of all 
patients reported the presence of at least one chronic physical health condi- 
tion on the GHS at intake. The most frequently endorsed physical conditions 
included mitral valve prolapse (17%), asthma (11%), thyroid disease (9%), 
high blood pressure (9%), and other (16%; e.g., reflux, Hepatitis C, various 
cardiac onditions). 
Demographic Comparisons Between Groups 
Baseline differences between CBT-treated patients and delayed-treatment 
controls were examined using an independent t est for age and chi-square 
tests for categorical variables (i.e., sex, ethnicity, marital status, and employ- 
ment status). Participants in the two groups did not significantly differ on any 
of the demographic variables at baseline (ps > .05). 
Pretreatment toPosttreatment Effects of CBT 
on Anxiety and Physical Health 
In order to establish that the treatment significantly decreased both anxiety 
symptoms and physical health problems, mixed design analyses of variance 
(ANOVAs) were conducted with each of three dependent variables. SPRAS 
and PDSS scores represented anxiety symptoms and PHRF scores repre- 
sented physical health outcomes. Two time points--pretreatment a dpost- 
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TABLE 1 
GROUP EFFECTS ON ANXIETY AND HEALTH FROM 
PRETREATMENT TO POSTTREATMENT (ANOVAs)  
55 
Post- 
Pre-Treatment Treatment F Ratios (Partial ,q2) 
Group M SD M SD Group Time Interaction 
Dependent Variable = SPRAS 10.23"* 68.50*** 9.67** 
(.19) (.61) (.18) 
CBT 51.09 27.77 14.36 l 1.67 
WL 60.29 29.29 43.63 18.93 
Dependent Variable = PDSS 21.31"** 40.36*** 15.71"** 
(.33) (.48) (.27) 
CBT 1.87 0.70 0.54 0.45 
WL 2.09 0.81 t .78 0.72 
Dependent Variable = PHRF 7.31" 10.08"* 6.64** 
(.14) (.19) (.13) 
CBT 10.07 5.24 4.12 3.72 
WL 11.03 6.05 10.41 7.18 
Note. Sample size was 22 in the CBT group and 24 in the WL group with the exception of one 
participant in the WL group missing data on the PDSS. SPRAS = Sheehan Patient- 
Rated Anxiety Scale; CBT = cognitive behavioral therapy; WL = wait list; PDSS = 
Panic Disorder Severity Scale; PHRF = Physical Health Rating Form. 
*p < .05; **p < .01; ***p < .001. 
treatment--composed a within-subjects factor, while group status--CBT or 
wait list (WL)--was the between-subjects factor in each ANOVA. Table 1 
shows descriptive statistics for each outcome variable by time and group as 
well as the significance and effect sizes of group effects, changes across time, 
and the interaction of group by time on each outcome. 
As noted in Table 1, significant interaction effects emerged for each out- 
come variable. In addition, all main effects for group and time were signifi- 
cant. Examination of the marginal means reveals that, for each outcome vari- 
able, participants in the CBT group began with lower mean scores than 
participants in the WL group. Regardless of group, mean scores on both of 
the anxiety measures and the physical health measure decreased across time. 
However, participants in the CBT group demonstrated significantly (at least 
at the p < .01 level) greater reduction in both anxiety (SPRAS and PDSS) 
symptoms and physical health problems (PHRF) than participants in the WL 
group, showing the expected benefit of the treatment on both anxiety and 
physical health problems. In terms of clinical significance, partial .q2 values 
for the interactions uggested that being in the CBT group accounted for 13% 
of the change in PHRF scores over time, while accounting for 18% and 27% 
of the change in SPRAS and PDSS scores, respectively. 
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Mediation and Moderation Analyses 
Mediation. To determine whether the reduction in physical health prob- 
lems attributed to the group treatment may have been mediated by the reduc- 
tion in anxiety symptoms, we calculated residualized change scores on the 
SPRAS from pretreatment to midtreatment, and residualized change scores 
on the PHRF from midtreatment to posttreatment. The PDSS was not admin- 
istered at midtreatment and was therefore xcluded from analyses of potential 
mediation. The following four conditions for mediation (Baron & Kenny, 
1986) would be met if the treatment intervention caused a reduction in anxi- 
ety and that reduction in anxiety caused a subsequent reduction in physical 
health problems. First, the treatment would significantly predict he initial 
change in anxiety. Second, the treatment would also predict he more distal 
changes in physical health problems. Third, the initial change in anxiety 
would significantly predict he subsequent change in physical health prob- 
lems when controlling for the effect of treatment, which, finally, would be 
substantially reduced compared to its original effect when used alone to pre- 
dict change in physical health problems. 
We conducted two linear regression analyses to evaluate the three conditions 
for mediation. The results in Table 2 fail to provide evidence for mediation. 
Although the treatment predicted both SPRAS score reductions from pre- to 
midtreatment ([3 = - .48,  p < .01) and PHRF score reductions from mid- 
to posttreatment (13= - .42, p < .05), the bottom portion of the table shows 
that changes in anxiety (residualized SPRAS scores) failed to predict subse- 
quent changes in PHRF scores at the o~ = .05 level ([3 = .15,p -- .41) after 
accounting for the impact of the treatment intervention. 
TABLE 2 
LINEAR REGRESSION RESULTS FROM ANXIETY MEDIATION ANALYSES 
Adjusted Predictors 
Outcome Variable Step R 2 Included B SE B 
Residual SPRAS 1 .20 Group - 16.08 5.16 - .48**  
Residual PHRF 1 .15 Group -3 .79  1.45 - .42*  
2 .14 Group -3 .12  1.65 - .34"  
Residual SPRAS .04 .05 .15 
Note. "Residual SPRAS" refers to the residual values after regressing SPRAS scores at 
midtreatment on SPRAS scores at pretreatment. "Residual PHRF" refers to the residual 
values after regressing PHRF scores at posttreatment on PHRF scores at midtreatment. 
For the treatment group n = 20 and for the wait-list group n = 15 due to missing data at 
the midtreatment collection point. "Group" was coded as follows: cognitive behavioral 
treatment = 1, wait list = 0. SPRAS = Sheehan Patient-Rated Anxiety Scale; PHRF = 
Physical Health Rating Form. 
aApproaches significance,p < .10. 
*p < .05; **p < .01. 
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Moderation. We conducted a 2 (within subjects, pretreatment versus post- 
treatment) by 2 (between subjects, CBT or WL group) by 2 (between sub- 
jects, presence versus absence of any chronic illness reported in the GHS) 
mixed design ANOVA to investigate whether the observed impact of the 
treatment intervention on the reduction of physical health problems depended 
upon the presence of a chronic illness (N = 46 for the analysis, with n = 26 
participants reporting a chronic illness). In the full-factorial model, the three- 
way interaction of time by group by chronic illness status was not significant 
at the o~ = .05 level, F(1, 42) = .09, p = .76. Therefore, no evidence was 
observed for the presence of a chronic illness affecting the impact of the 
treatment across time on physical health changes. 
Results Through Follow-up for the CBT Group 
Within the CBT group, for which 6-month follow-up data were collected, 
changes in physical health (PHRF) as well as changes in anxiety (SPRAS) 
were evaluated across all four time points (pretreatment, midtreatment, post- 
treatment, and 6-month follow-up) using two univariate repeated measures 
ANOVAs. Unequal intervals of 5 weeks from pretreatment to midtreatment, 
10 weeks from pretreatment to posttreatment, and 36 weeks from pretreat- 
merit to 6-month follow-up were specified in the model. Linear, quadratic, 
and cubic polynomial effects were included. Of the 19 participants who con- 
tributed at least some follow-up data, 2 were excluded from the ANOVA 
examining PHRF scores over time because of missing data on this measure at 
follow-up, and 2 others were excluded from the ANOVA examining SPRAS 
scores because of missing data at midtreatment, resulting in n = 17 for each 
analysis. 
For the polynomial ANOVA examining SPRAS scores over time, overall 
F(1.86, 29.83) = 22.97, p < .001, after applying a Huynh-Feldt Epislon cor- 
rection for violation of the sphericity of variance assumption. This indicated 
an overall effect of time on SPRAS scores. Follow-up tests of polynomial 
effects showed significant linear, F(1, 16) = 29.74, p < .001, quadratic, 
F(1, 16) = 33.26, p < .001, and cubic, F(1, 16) = 6.02, p < .05, effects of 
time on SPRAS scores. In the PHRF ANOVA, time effects were also signifi- 
cant overall, F(3, 48) = 23.42, p < .001, as were follow-up tests of linear, 
F(1, 16) = 30.64, p < .001, and quadratic, F(1, 16) = 30.41, p < .001, 
trends. The cubic effect was not significant, F(1, 16) = 3.78, p = .07. Figure 
1 depicts the pattern of findings for both outcome measures. 
As a further test of the nature of the significant trends, post hoc t tests of all 
pairwise comparisons across time were conducted within each repeated mea- 
sures ANOVA, applying a Bonferroni adjustment to the resulting significance 
levels. For the SPRAS, pretreatment scores differed from scores at each other 
time point with at least p < .01 significance. Pretreatment PHRF scores also 
differed from scores at each other time point with at least p < .001 signifi- 
cance. The remaining time points did not differ from one another (at the o~ = 
.05 level) for either outcome measure. Figure 1 shows the decrease in both 
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FIG. 1. Sheehan Patient-Rated Anxiety Scale (SPRAS) scores and Physical Health Rating 
Form (PHRF) scores from pretreatment through follow-up in the cognitive behavioral treatment 
group (n = 17 for each variable). The double and triple asterisks denote that pretreatment 
scores on the SPRAS and PHRF, respectively, differed from scores at the other three time points 
with at least p < .01 (SPRAS) and p < .001 (PHRF) significance, respectively, after Bonferroni 
correction for all possible comparisons among time points for each variable using t tests. Scores 
from midtreatment through follow-up did not differ significantly (p > .05) from each other for 
either measure after Bonferroni adjustment. 
anxiety and physical health problems from pretreatment to midtreatment that 
was maintained throughout the follow-up period. 
Discussion 
As far as we are aware, this is the first study to evaluate the effects of cog- 
nitive behavioral therapy for panic disorder on physical health status. Consis- 
tent with many other studies, we have demonstrated that cognitive behavioral 
therapy has a significant impact on anxiety symptoms. Of particular interest 
here, we also found that cognitive behavioral therapy for panic disorder led to 
improvements on physical health status as measured by a composite self- 
report rating scale. The fact that significant changes in physical health status 
were already evident by midtreatment suggests that CBT can also produce 
fairly rapid benefits in relation to physical health. 
Interestingly, mediation analyses indicated that changes in anxiety symp- 
toms did not account for the relationship between treatment and the physical 
health variables at posttreatment. This would suggest that treatment may be 
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affecting physical health tbxough some other mechanism. One possibility is 
that general affective distress or depression may be acting as a mediating 
variable. This alternative hypothesis consistent with the fact that CBT has a 
notable impact on depression symptoms and that depression has a negative 
impact on physical health (Badger, 1998; Druss, Allen, & Bruce, 1998; Judd, 
Paulus, Wells, & Rapaport, 1996). To investigate his, we conducted additional 
post hoc mediation analyses evaluating changes in depression symptoms as a 
potential mediator variable. However, these analyses did not yield convincing 
evidence of mediation. Taken together, there is little evidence to suggest that 
changes in distress mediated the relationship between CBT and physical health. 
An alternative hypothesis that the changes noted in physical health status 
may be a result of changes in psychological orcognitive factors that influence 
perceptions of physical health symptoms. Attention or vigilance to bodily 
sensations has taken on increased importance inpsychological conceptualiza- 
tions of panic. For example, cognitive models of panic (Barlow, 1988; Clark, 
1986) suggest that patients may become vigilant o bodily arousal as a conse- 
quence of experiencing panic attacks. Related to this, patients with panic dis- 
order appear to have greater interoceptive accuracy (Ehlers & Breuer, 1992). 
In fact, some of our earlier work confirms the fact that patients with panic 
disorder are more consciously vigilant o bodily sensations relative to con- 
trols and other anxiety disorders (Schmidt, Lerew, & Trakowski, 1997). Con- 
ceivably, increased interoceptive acuity or increased attention to bodily cues 
may result in increased reporting of physical health symptoms. CBT proto- 
cols for panic disorder attempt to target interoceptive processes (e.g., Barlow 
& Craske, 2000). Moreover, Schmidt, Lerew, et al. (1997) found that vigi- 
lance to bodily sensations was significantly diminished following CBT for 
panic disorder. Therefore, patients in the present study may simply be less 
aware of physical symptoms that they had previously attributed to a medical 
condition. Unfortunately, it is impossible to know whether the treatment actu- 
ally influenced physical health status or whether the treatment simply altered 
perceptions of physical health in the present study. Future work involving 
biological parameters is critical to more fully address this issue. 
An important consideration regarding the study findings is that nonpsychi- 
atric medical morbidity was based on patient self-report instead of examina- 
tions by physicians or laboratory methods. Self-report of physical symptoms 
as opposed to health measures obtained from a comprehensive physical exami- 
nation is an obvious methodological limitation that leaves open the question of 
whether patients with panic disorder can reliably report nonpsychiatric medical 
symptoms. Despite potential problems, self-reported health symptoms have 
been shown to be highly associated with actual health status (LaRue, Bank, 
Jarvik, & Hetland, 1979; Mossey & Shapiro, 1982). For example, Bradford, 
Graham, and Reinert (1993) found that only 4% of their patient sample had 
significant discrepancies between self-reported medical conditions and docu- 
mented medical histories. Thus, there is reason to believe that the self-report 
methodology used in the present study is likely to adequately represent 
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physical health symptoms. However, it is recommended that additional work 
exploring this relationship should utilize objective physical health measures. 
It is also important to consider that subjective or perceived physical health 
often provides an accurate gauge of physical health outcomes. A number of 
prospective r ports have found that perceived health predicts mortality (Idler 
& Angel, 1990; Idler & Kasl, 1991; Idler, Kasl, & Lemke, 1990; Kaplan & 
Camacho, 1983; Mossey & Shapiro, 1982). In fact, perceived physical health 
has been found to predict mortality better than the presence of health prob- 
lems (Idler & Kasl) or health status assessed by physicians (Mossey & Sha- 
piro). There is also evidence to suggest that perceived health and actual dis- 
ease severity are independently related to illness-specific anxiety symptoms. 
For example, Carr, Lehrer, and Hochron (1995) found that asthma patients' 
subjective reports of asthma symptomatology and pulmonary function tests 
independently predicted asthma-related panic fear. Thus, perceived physical 
health may predict consequential mental and physical health outcomes in 
patients with panic disorder. 
The limitations of this study need to be considered. The sample size was 
modest, particularly for the follow-up analyses. Because some of the findings 
amount to accepting the null hypothesis (e.g., lack of moderation effects), it
is possible that the effects are a result of low statistical power. Therefore, rep- 
lication is certainly warranted. Another limitation of the present report 
involved collapsing across many different forms of health problems. Because 
of the sample size in the present study, it is not feasible to separately evaluate 
each specific medical condition. This type of measurement approach may 
obscure potentially salient effects. For example, it may be that CBT differen- 
tially affects milder versus more severe medical conditions. It is also impor- 
tant to note that the majority of identified medical problems in the present 
study were relatively mild (e.g., MVP, high blood pressure). Other samples 
containing a preponderance of more severe medical conditions (e.g., COPD, 
heart disease) may produce adifferent pattern of findings. 
The present study points to the complex interplay between panic disorder 
and physical health outcomes. Consistent with expectations, data indicate 
that CBT affects mental health and physical symptoms. Future work utilizing 
biological indicators is needed, however, to more definitively demonstrate 
this effect. 
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